{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:50:03Z","timestamp":1747155003565,"version":"3.40.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.annder.2024.103280","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T05:10:56Z","timestamp":1716354656000},"page":"103280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers and suggestions for improving the implementation of guidelines in the systemic treatment of moderate to severe psoriasis: A literature review"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4105-2838","authenticated-orcid":false,"given":"V.","family":"Kalita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Abs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-C.","family":"Bursztejn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103280_b0005","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2024.103280_b0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12955-021-01902-w","article-title":"Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study","volume":"19","author":"Zhong","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annder.2024.103280_b0015","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annder.2024.103280_b0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jdv.16601","article-title":"Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis","volume":"34","author":"Villani","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00403-013-1341-x","article-title":"National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines","volume":"305","author":"Nast","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2024.103280_b0030","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"29","author":"Van de Kerkhof","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","article-title":"Under-treatment of patients with moderate to severe psoriasis in the united states: analysis of medication usage with health plan data","volume":"7","author":"Armstrong","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.annder.2024.103280_b0040","doi-asserted-by":"crossref","first-page":"1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.annder.2024.103280_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12875-016-0544-6","article-title":"Severity and management of psoriasis within primary care","volume":"17","author":"Wade","year":"2016","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.annder.2024.103280_b0050","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2230.2010.04011.x","volume":"36","author":"Bewley","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2024.103280_b0055","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.14811","article-title":"Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria","volume":"32","author":"Schielein","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0060","first-page":"833","article-title":"Systemic treatment with corticosteroids in psoriasis\u2013health care provision far beyond the S3-guidelines","volume":"9","author":"Augustin","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2024.103280_b0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00403-009-0978-y","article-title":"Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines","volume":"301","author":"Nast","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2024.103280_b0070","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/jdv.17220","article-title":"Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004\u20132017","volume":"35","author":"Langenbruch","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0075","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2753.2008.00971.x","article-title":"Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination","volume":"14","author":"Nast","year":"2008","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.annder.2024.103280_b0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000218161","article-title":"Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators","volume":"219","author":"Radtke","year":"2009","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.annder.2024.103280_b0085","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/jid.2010.164","article-title":"Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006\u20132009","volume":"130","author":"Tan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103280_b0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaad.2015.11.045","article-title":"Translating psoriasis guidelines into practice: Important gaps revealed","volume":"74","author":"Bhushan","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103280_b0095","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2007.06.042","article-title":"Are patients with psoriasis undertreated? results of national psoriasis foundation survey","volume":"57","author":"Horn","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103280_b0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ad.2012.10.019","article-title":"Expert report on psoriasis: Spanish dermatologists\u2019 opinions on the use of biologic agents to manage moderate to severe psoriasis in adults","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.annder.2024.103280_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004179","article-title":"Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil","volume":"4","author":"Silveira","year":"2014","journal-title":"BMJ Open."},{"key":"10.1016\/j.annder.2024.103280_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000102033","article-title":"Dermatologists\u2019 adherence to the guideline of the Dutch Society of Dermatology and Venereology with respect to the treatment with methotrexate for severe chronic plaque psoriasis: results from a Dutch survey","volume":"215","author":"Berends","year":"2007","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.annder.2024.103280_b0115","first-page":"426","article-title":"Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists","volume":"159","author":"Wakkee","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103280_b0120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00403-013-1372-3","article-title":"Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis\u2013a multinational cross-sectional study","volume":"305","author":"Nast","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2024.103280_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/00015555-2857","article-title":"Methotrexate management in psoriasis: are we following the guidelines?","volume":"98","author":"Lindqvist","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1468-3083.2009.03166.x","article-title":"A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: \u201cAGREE-ing\u201d on a common base for European evidence-based psoriasis treatment guidelines","volume":"23","author":"Nast","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0135","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.13222","article-title":"Use of biologics for psoriasis in Central and Eastern European countries","volume":"29","author":"Rencz","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103280_b0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00403-016-1637-8","article-title":"The german national program on psoriasis health care 2005\u20132015: results and experiences","volume":"308","author":"Augustin","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2024.103280_b0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7861\/clinmedicine.14-2-178","article-title":"Psoriasis: guidance on assessment and referral","volume":"14","author":"Samarasekera","year":"2014","journal-title":"Clin Med"},{"key":"10.1016\/j.annder.2024.103280_b0150","unstructured":"GRPso. Groupe de Recherche sur le psoriasis. 2017. Available at: https:\/\/grpso.org\/ (last accessed 2 April 2023)."}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382400036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382400036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:27:00Z","timestamp":1716366420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196382400036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S015196382400036X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103280","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and suggestions for improving the implementation of guidelines in the systemic treatment of moderate to severe psoriasis: A literature review","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103280"}}